BSE - Free Realtime Quote INR

Sylph Technologies Limited (SYLPH.BO)

0.8700

0.0000

(0.00%)

As of 1:19:14 PM GMT+5:30. Market Open.

Dollar General, Lululemon, Broadcom: Earnings to Watch This Week

Asking for a Trend's Josh Lipton takes a look ahead to this week's biggest earnings releases, including chipmaker Broadcom (AVGO), Lululemon Athletica (LULU), CrowdStrike Holdings (CRWD), Hewlett Packard Enterprise (HPE), and discount retailers Dollar General (DG), Dollar Tree (DLTR), and Five Below (FIVE). To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here.

Yahoo Finance Video 20 hours ago

LULU

VSCO

RBRK
FTSE 100 LIVE: Markets slide as China accuses US of violating trade deal

Markets were volatile on Monday as Trump's tariff war continues to play out.

Yahoo Finance UK 12 minutes ago

ES=F

^FTSE

^FCHI
Oil Advances as OPEC+ Supply Boost Vies With Geopolitical Risk

(Bloomberg) -- Oil advanced as OPEC+ hiked production less than some had feared and geopolitical concerns flared over Ukraine and Iran.Most Read from BloombergBillionaire Steve Cohen Wants NY to Expand Taxpayer-Backed FerryWhere the Wild Children’s Museums AreThe Economic Benefits of Paying Workers to MoveNow With Colorful Blocks, Tirana’s Pyramid Represents a Changing AlbaniaNYC Congestion Toll Brings In $216 Million in First Four MonthsBrent crude for August rose toward $65 a barrel after losi

Bloomberg 2 hours ago

BZ=F

CL=F
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint.

PR Newswire 2 hours ago

BPMC

SNY

SNYNF
Sanofi to buy US biopharma group Blueprint for over $9 billion

PARIS (Reuters) -France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost its position in rare immunology diseases, in what would be the biggest healthcare deal in Europe this year, according to LSEG data. Blueprint is a specialist in treatments for systemic mastocytosis, a rare immunological disorder. The two companies said on Monday that Sanofi would pay $129.00 per share in cash.

Reuters 2 hours ago

SNY

BPMC
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.

The Wall Street Journal 2 hours ago

SNY

SNYNF

BPMC
How much does it cost to become a driver in the UK?

Costs include driving lessons, insurance and the car itself — and it all adds up.

Yahoo Finance UK 3 hours ago

GBPUSD=X

USD=X

GBP=X
Investors say they took advantage of market instability caused by Trump’s tariffs

Stock markets around the world suffered sharp drops in the days following the so-called ‘liberation day’ announcements

The Independent 9 hours ago

^FTSE

^GSPC
Millennial investors bought cheap stocks in Trump tariffs market turmoil

The age group took advantage of the volatility that swept across the world’s financial markets, research shows.

PA Media: Money 9 hours ago

^FTSE

^GSPC
1 Stock to Buy, 1 Stock to Sell This Week: Broadcom, Lululemon

Stocks on Wall Street ended lower on Friday, but the major indices notched a weekly gain and the biggest monthly increase since late 2023 as investors shook off trade war fears.

Investing.com 18 hours ago

AVGO

LULU
Street Calls of the Week

Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week.

Investing.com 22 hours ago

CLF

MSM

FICO
Dollar Tree, Lululemon, layoffs, and jobs numbers: What to watch in the stock market this week

It’s a new month, and investors are heading into it amid fresh inflation data and rising pessimism that’s dominating headlines. With the Fed’s next meeting now just weeks away, all eyes will be on Friday’s jobs report, which could shape expectations for rate cuts this summer.

Quartz 23 hours ago

LULU
NIO Inc. Provides May 2025 Delivery Update

23,231 vehicles were delivered in May 2025, increasing by 13.1% year-over-year89,225 vehicles were delivered year-to-date in 2025, increasing by 34.7% year-over-yearCumulative deliveries reached 760,789 as of May 31, 2025 SHANGHAI, June 01, 2025 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its May 2025 delivery results. The Company delivered 23,231 vehicles in

GlobeNewswire 23 hours ago

NIO

NIOIF
'Reformer pilates is the top-searched fitness trend — and we're reinventing it'

Founded in 2018 by a husband and wife team, Reform RX set out to create a world-first connected pilates reformer.

Yahoo Finance UK yesterday

HLT

GBPEUR=X

GBP=X
MP Materials (NYSE:MP) Reports Q1 Net Loss Despite Increase In REO Production

MP Materials (NYSE:MP) recently signed a Memorandum of Understanding with the Saudi Arabian Mining Company to develop a rare earth supply chain in Saudi Arabia, aligning with growing global demands. Despite reporting a net loss for the first quarter, the company increased its REO and NdPr production volumes. Additionally, no shares were repurchased in the recent buyback tranche, reflecting existing efforts. Over the past week, the company's share price rose by 11%, notably outperforming the...

Simply Wall St. yesterday

MP
Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports 27% Reduction In COPD Exacerbations In Phase 3 Trial

Regeneron Pharmaceuticals (NasdaqGS:REGN) announced favorable Phase 3 trial results for itepekimab and entered a significant licensing agreement with Telesis Bio, enhancing its R&D capabilities. Despite these positive developments, the company's shares fell by 17% last week. In contrast, the broader market rose by 1.7%. This divergence might suggest that the market's reaction to Regeneron's news was mixed or that other factors were at play. While the trial success and new partnership could...

Simply Wall St. yesterday

REGN
Better AI Stock: Palantir vs. BigBear.ai

Palantir and BigBear.ai are artificial intelligence (AI) stocks involved in the defense industry. Both companies are also working to move beyond the U.S. government. Two of the leading artificial intelligence (AI) stocks over the past year are Palantir Technologies (NASDAQ: PLTR) and BigBear.ai (NYSE: BBAI).

Motley Fool yesterday

PLTR

BBAI-WS

PYPL
Palantir, JPMorgan Chase Lead Five Stocks Near Buy Points

Palantir Technologies has been getting no shortage of good news from the Trump administration as other contractors struggle.

Investor's Business Daily yesterday

EAT

DASH

COST
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of locoregional and distant recurrence, respectively, compared to placebo Detailed results presented in an oral session at the 2025 American Society of Clinical Oncology Annual Meeting and simultaneously published in the New England Journal of Medicine Regulatory applications have been submitted in the United St

GlobeNewswire yesterday

REGN
The Weekend: Food inflation dampens hopes of a rate cut as tariff twists and turns continue

Key moments from the last seven days, plus a glimpse at the week ahead

Yahoo Finance UK yesterday

LULU

AVGO

NVDA

Performance Overview

Return	SYLPH.BO	S&P BSE SENSEX (^BSESN)
YTD	-22.32%	+4.05%
1-Year	-57.35%	+9.93%
3-Year	-45.18%	+45.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sylph Technologies Limited (SYLPH.BO)

Related News

Dollar General, Lululemon, Broadcom: Earnings to Watch This Week

FTSE 100 LIVE: Markets slide as China accuses US of violating trade deal

Oil Advances as OPEC+ Supply Boost Vies With Geopolitical Risk

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to buy US biopharma group Blueprint for over $9 billion

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

How much does it cost to become a driver in the UK?

Investors say they took advantage of market instability caused by Trump’s tariffs

Millennial investors bought cheap stocks in Trump tariffs market turmoil

1 Stock to Buy, 1 Stock to Sell This Week: Broadcom, Lululemon

Street Calls of the Week

Dollar Tree, Lululemon, layoffs, and jobs numbers: What to watch in the stock market this week

NIO Inc. Provides May 2025 Delivery Update

'Reformer pilates is the top-searched fitness trend — and we're reinventing it'

MP Materials (NYSE:MP) Reports Q1 Net Loss Despite Increase In REO Production

Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports 27% Reduction In COPD Exacerbations In Phase 3 Trial

Better AI Stock: Palantir vs. BigBear.ai

Palantir, JPMorgan Chase Lead Five Stocks Near Buy Points

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

The Weekend: Food inflation dampens hopes of a rate cut as tariff twists and turns continue

Performance Overview